Results 41 to 50 of about 580 (130)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?

ImmunoTargets and Therapy, 2020
Ana Lorenzo-Vizcaya,1 Serena Fasano,2 David A Isenberg3 1Department of Internal Medicine, Hospital Universitario De Ourense, Ourense, Spain; 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Campania L.
Lorenzo-Vizcaya A, Fasano S, Isenberg DA
doaj  

Protein Posttranslational Modifications in Immunity: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 9, September 2026.
Protein posttranslational modifications, including phosphorylation, ubiquitination, SUMOylation, acetylation, methylation, glycosylation, and other new types, dynamically regulate antigen presentation and recognition, immune signal transduction, antibody production and class switching, immune contraction, immune memory establishment, as well as immune ...
Yuxing Yao, Jinxiu Qian, Qiqiong Liu, Wanting Ye, Ying Xing, Xiuyun Bai, Rongjun Deng, Jue Yang, Cheng Lu, Cheng Xiao, Yuanyan Liu   +10 more
wiley   +1 more source

Chemical Process Development in the Pharmaceutical Industry in Europe—Insights and Perspectives from Industry Scientists

Angewandte Chemie, Volume 137, Issue 19, May 5, 2025.
What are the tasks of chemical process development in the pharmaceutical industry? What are trends and challenges? This Scientific Perspective written by members of the European pharmaceutical industry introduces key concepts of drug development and key drivers for the future of chemical process development.
Joachim Krueger, André P. Dieskau, Jorma Hassfeld, Joerg Gries, Oliver Block, Hilmar Weinmann, Daniel Kaufmann, Stefan Hildbrand, Volker Kraft, Robert Moeckel, Juan R. Dehli, Ulrich Scholz, Carl Friedrich Nising   +12 more
wiley   +2 more sources

OP0025 FENEBRUTINIB COMPARED TO PLACEBO AND ADALIMUMAB IN PATIENTS WITH INADEQUATE RESPONSE TO EITHER METHOTREXATE THERAPY OR PRIOR TNF THERAPY: PHASE 2 STUDY [PDF]

Annals of the Rheumatic Diseases, 2019
Background Fenebrutinib (GDC-0853, FEN) is a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) that is orally administered, highly selective, non-covalent, and reversible. Objectives This study evaluated the efficacy and safety of FEN compared with placebo (PBO) and adalimumab (ADA), in combination with background methotrexate (MTX), in ...
Stanley Cohen, Katie Tuckwell, Tamiko R. Katsumoto, Rui Zhao, Chin Lee, Alberto Berman, Nemanja Damjanov, Dmytro Fedkov, Sławomir Jeka, Mark C. Genovese   +9 more
openaire   +1 more source

Time to Meaningful Clinical Response Across Approved and Emerging Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis [PDF]

J Clin Med
Background/Objectives: Several novel biologics and small-molecule therapies have emerged for the treatment of antihistamine-refractory chronic spontaneous urticaria (CSU), yet no study has directly compared their speed of response.
Balachandar S, Clapp D, Fleischer A.
europepmc   +2 more sources

Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.
ABSTRACT The 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase inhibitor rosuvastatin is a substrate of breast cancer resistance protein (BCRP). BCRP inhibition increases rosuvastatin plasma concentrations and may result in concentration‐dependent muscle toxicity, at worst rhabdomyolysis.
Ronja Levomäki, Päivi Hirvensalo, Aleksi Tornio, Anne M. Filppula   +3 more
wiley   +1 more source

Evolution of Drug Development Trends in Multiple Sclerosis: Analysis of Mainland China and Global Landscapes From 2004 to 2024

CNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
This registry‐based analysis of 1183 MS clinical trials (2004–2024) shows sustained global activity and a marked increase in mainland China after 2018, predominantly driven by late‐phase and bioequivalence studies. Trial density varied across regions, and IFNAR, CD20, and S1PR1 were the most frequently investigated targets. ABSTRACT Background Multiple
Chaoyang Chen, Zhenyu Niu, Ting Yang, Xuanling Zhang, Ran Wei, Xiaocong Pang, Ran Liu, Ying Zhou   +7 more
wiley   +1 more source

Autoimmune chronic spontaneous urticaria

, 2022
18191831Chronic spontaneous urticaria (CSU) is a debilitating mast cell-driven disease characterized by recurrent wheals and/or angioedema. Substantial progress has been made in dissecting the 2 main autoimmune mechanisms that drive the pathogenesis of ...
Xiang, Yi-Kui, Ferrer, M., Asero, R., Kocatürk, E., Muñoz, Melba, Metz, Martin, Maurer, Marcus, Kolkhir, Pavel   +7 more
core   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

British Journal of Clinical Pharmacology, Volume 91, Issue 8, Page 2340-2351, August 2025.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano   +4 more
wiley   +1 more source

Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton’s Tyrosine Kinase

, 2021
High platelet reactivity leading to spontaneous platelet aggregation (SPA) is a hallmark of cardiovascular diseases; however, the mechanism underlying SPA remains obscure.
Luise Goldmann, Ya Li, Philipp von Hundelshausen, Rundan Duan, Christian Weber, Wolfgang Siess   +5 more
core   +1 more source